The effect of varying the screening interval on false positives and duration of undiagnosed disease in a screening programme for type 2 diabetes

被引:8
作者
Park, PJ
Griffin, SJ
Duffy, SW
Wareham, NJ
机构
[1] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England
[2] MRC, Biostat Unit, Cambridge CB2 2BW, England
关键词
progression; type; 2; diabetes; IGT; oral glucose tolerance test; false positives; undiagnosed diabetes;
D O I
10.1136/jms.7.2.91
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives-The aims of this study were to quantify the proportion of people diagnosed as having type 2 diabetes by standard 75 g oral glucose tolerance test, in a hypothetical screening programme, who would actually be false positives (false positive percentage), and the effect on the false positive percentage of varying the time between repeat screens. We also calculated the duration in person years of exposure to undiagnosed disease in the population for each screening interval. Setting-Ely, Cambridgeshire, UK. Methods-We used the glucose tolerance data from 965 participants of the fly Diabetes Project, who were tested 4.5 years apart, to calculate the population's between and within person variance for 2 hour plasma glucose, and constructed a probability matrix of observed v true glucose tolerance categories. The progression of the population between glucose tolerance categories was modelled assuming exponential times to progression. Results-After one year, 47.5% of test positives were disease free: almost half of those labelled with diabetes would not have the disease. For a 5 year interval, the false positive percentage was 27.6%, but the population would have been exposed to undiagnosed diabetes for 144 person years. Conclusions-Screening can be associated with both benefit and harm; the balance is dependent on characteristics of the disease and the screening programme. This study has quantified the trade off between exposure to undiagnosed diabetes and false positive results to inform the debate about screening for type 2 diabetes.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 50 条
[1]   LABELING OF HYPERTENSIVES - A REVIEW OF THE DATA [J].
ALDERMAN, MH ;
LAMPORT, B .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1990, 43 (02) :195-200
[2]  
Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO
[3]  
2-I
[4]   HYPERTENSION LABELING AND SENSE OF WELL-BEING [J].
BLOOM, JR ;
MONTEROSSA, S .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1981, 71 (11) :1228-1232
[5]  
BRAID E, 1992, DIABETIC MED, V9, P389
[6]   THE AMERICAN-DIABETES-ASSOCIATION SCREENING QUESTIONNAIRE FOR DIABETES - IS IT WORTHWHILE IN THE UK [J].
BURDEN, ML ;
BURDEN, AC .
DIABETES CARE, 1994, 17 (01) :97-97
[7]   DIABETES-MELLITUS IN TECUMSEH, MICHIGAN - PREVALENCE, INCIDENCE, AND ASSOCIATED CONDITIONS [J].
BUTLER, WJ ;
OSTRANDER, LD ;
CARMAN, WJ ;
LAMPHIEAR, DE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 116 (06) :971-980
[8]  
Colton T., 1974, STAT MED, P38
[9]   FREQUENCY AND DETERMINANTS OF SCREENING FOR DIABETES IN THE US [J].
COWIE, CC ;
HARRIS, MI ;
EBERHARDT, MS .
DIABETES CARE, 1994, 17 (10) :1158-1163
[10]  
Davies M, 1994, J Med Screen, V1, P78